JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

REVOLUTION Medicines Inc

Open

SectorGezondheidszorg

38.43 3.39

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

36.45

Max

38.47

Belangrijke statistieken

By Trading Economics

Inkomsten

-19M

-213M

EPS

-1.13

Winstmarge

-74.379

Werknemers

616

EBITDA

-24M

-237M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+83.48% upside

Dividenden

By Dow Jones

Volgende Winsten

6 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-644M

6.9B

Vorige openingsprijs

35.04

Vorige sluitingsprijs

38.43

Nieuwssentiment

By Acuity

50%

50%

175 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

REVOLUTION Medicines Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 aug 2025, 21:42 UTC

Winsten
Acquisities, Fusies, Overnames

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 aug 2025, 21:21 UTC

Winsten
Belangrijke Marktbewegers

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 aug 2025, 20:45 UTC

Winsten

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 aug 2025, 19:15 UTC

Belangrijke Marktbewegers

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 aug 2025, 23:41 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

4 aug 2025, 23:41 UTC

Marktinformatie

Nikkei May Rise on Fed Stimulus Hopes

4 aug 2025, 23:28 UTC

Marktinformatie

Global Equities Roundup: Market Talk

4 aug 2025, 23:28 UTC

Marktinformatie

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 aug 2025, 21:30 UTC

Winsten

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug 2025, 21:21 UTC

Winsten
Acquisities, Fusies, Overnames

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 aug 2025, 21:18 UTC

Winsten

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug 2025, 20:25 UTC

Marktinformatie

India Hits Back Over Russian Oil Purchases -- Market Talk

4 aug 2025, 20:25 UTC

Winsten

Transocean 2Q Loss $938M >RIG

4 aug 2025, 20:25 UTC

Winsten

Transocean 2Q Loss/Shr $1.06 >RIG

4 aug 2025, 20:18 UTC

Winsten

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 aug 2025, 20:15 UTC

Winsten

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 aug 2025, 20:14 UTC

Winsten

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 aug 2025, 20:14 UTC

Winsten

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 aug 2025, 20:14 UTC

Winsten

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 aug 2025, 20:13 UTC

Winsten

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 aug 2025, 20:09 UTC

Winsten

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 aug 2025, 20:06 UTC

Winsten

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 aug 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 aug 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 aug 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 aug 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 aug 2025, 19:41 UTC

Marktinformatie

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 aug 2025, 19:28 UTC

Marktinformatie

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 aug 2025, 19:07 UTC

Marktinformatie

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 aug 2025, 18:27 UTC

Marktinformatie

Gold Climbs on Rate Cut Speculation -- Market Talk

Peer Vergelijking

Prijswijziging

REVOLUTION Medicines Inc Prognose

Koersdoel

By TipRanks

83.48% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 67.21 USD  83.48%

Hoogste 80 USD

Laagste 37.91 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor REVOLUTION Medicines Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

10

Buy

0

Hold

0

Sell

Technische score

By Trading Central

40.67 / 41.96Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

175 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.